Medicofarma Biotech Past Earnings Performance

Past criteria checks 0/6

Medicofarma Biotech's earnings have been declining at an average annual rate of -49%, while the Life Sciences industry saw earnings growing at 13.9% annually. Revenues have been declining at an average rate of 15.3% per year.

Key information

-49.0%

Earnings growth rate

10.5%

EPS growth rate

Life Sciences Industry Growth26.0%
Revenue growth rate-15.3%
Return on equity-31.4%
Net Margin-199.6%
Next Earnings Update14 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Medicofarma Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

WSE:MDB Revenue, expenses and earnings (PLN Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 241-300
31 Mar 241-200
31 Dec 231-300
30 Sep 231-200
30 Jun 231-200
31 Mar 231-200
31 Dec 224-200
30 Sep 225-200
30 Jun 226-100
31 Mar 226-100
31 Dec 213000
30 Sep 213000
30 Jun 213010
31 Mar 213-110
31 Dec 204-110
30 Sep 204010
30 Jun 203010
31 Mar 203010
31 Dec 193010
30 Sep 194010
30 Jun 195010
31 Mar 195010
31 Dec 185010
30 Sep 185010
30 Jun 185010
31 Mar 185010
31 Dec 175010
30 Sep 175010
30 Jun 175010
31 Mar 174010
31 Dec 164010
30 Sep 164010
30 Jun 164010
31 Mar 164010
31 Dec 154010
30 Sep 154010
30 Jun 154010
31 Mar 154010
31 Dec 144010
30 Sep 144010
30 Jun 145010
31 Mar 145010
31 Dec 135010

Quality Earnings: MDB is currently unprofitable.

Growing Profit Margin: MDB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MDB is unprofitable, and losses have increased over the past 5 years at a rate of 49% per year.

Accelerating Growth: Unable to compare MDB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDB is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-0.7%).


Return on Equity

High ROE: MDB has a negative Return on Equity (-31.41%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies